


CORPORATE PROFILE

Innovative Trauma Care, Inc. (ITC) is an early stage medical device company focused on developing and marketing point of injury solutions to address the common causes of preventable death in traumatic injury scenarios. Founded and incorporated in Edmonton, Canada in 2010, with a US headquarters in San Antonio, Texas, ITC's premier product is the ITClamp[™] Hemorrhage Control System, which addresses the number one cause of preventable death in trauma scenarios – massive hemorrhage.

PRODUCT PROFILE

The ITClamp[™] Hemorrhage Control System, ITC's first product, is a temporary wound closure device to control severe bleeding within seconds of a penetrating injury. The ITClamp seals the edges of a wound closed to create a temporary pool of blood under pressure, which forms a stable clot until the wound can be surgically repaired. No comparable product exists in the point-of-injury space, solving an unmet medical need.

- Fast and Effective – fluid and airtight seal of the skin in a matter of seconds
- Versatile – can be used in nearly every traumatic injury scenario
- Intuitive – requires only minimal training and gross motor skills
- Compact, light and durable – each ITClamp measures less than 2 by 2 inches



BACKGROUND

Bleeding is one of the leading causes of preventable death in North America. After a traumatic injury, hemorrhage is responsible for over 35 percent of pre-hospital deaths and over 40 percent of deaths within the first 24 hours¹. Early control of bleeding is critical to the survival of trauma patients in both military and civilian settings. In recent military operations uncontrolled hemorrhage was the primary cause of battlefield death. In particular, junctional hemorrhage, which is not amenable to tourniquet use, is a leading cause of preventable death among Canadian and U.S. soldiers. Recent estimates suggest that up to 4.6 percent of casualties during the current war could have been saved with a device that effectively treated junctional hemorrhage.

In the pre-hospital and emergency space focused on traumatic injury such as motor vehicle accidents, penetrating wounds, and wounds as a result of violent encounters, early trauma is focused on stopping the bleeding.

Currently, bleeding is controlled by the use of tourniquets, direct pressure, and wound packing (with or without hemostatic agents). These options are appropriate for various types of injuries but none offer the versatility to address multiple types of traumatic injuries with one device.

itClampTM Current Competitors

Product Name	TOURNIQUETS	HEMOSTATIC DRESSING	COMPRESSION BANDAGE	GROIN COMPRESSION CLAMP	ITClamp TM
Venous Bleeds	X	X	X		X
Arterial Bleeds – Extremity	X	X			X
Arterial Bleeds – Groin				X	X
Arterial Bleeds – Axilla (or base of neck)					X
Amputations	X				
Sucking Chest Wounds					X
Abdominal Eviscerations					X
Cost USD	\$ 30	\$ 43	\$ 8	\$ 450	\$ 79

1. National Trauma Institute - Kauvar, D.S., Lefering, R., and Wade, C.E. (2006) Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. *J Trauma* 60, S3-11

FREQUENTLY ASKED QUESTIONS

- **What is hemorrhage and why is it issue?**

Uncontrolled bleeding is a leading preventable cause of death in traumatic injury scenarios. After a traumatic injury, hemorrhage is responsible for 35 percent of pre-hospital deaths and over 40 percent of deaths within 24 hours after a traumatic injury. A first responder's primary goal is to control this bleeding before the patient deteriorates and possibly expires.

- **How do we currently address bleeding?**

The current methods to address hemorrhage – tourniquet, direct pressure and/or hemostatic agents – are appropriate for various types of injuries, but take training to effectively apply and are not applicable in a multitude of traumatic injuries. The ITClamp requires very little training to use, takes seconds to apply, can be used in most anatomical placements, and effectively stops bleeding in seconds.

- **What is the ITClamp and how does it work?**

The ITClamp is a single use, disposable plastic device with surgical needles and two pressure bars to create a fluid tight seal across the wound edges. This allows a hematoma (pool of blood) to form in contained space. As the pressure in the hematoma increases, there is no further flow into the space and a stable blood clot forms until the patient's wound can be surgically addressed.

- **How is the ITClamp better than current solutions?**

The ITClamp instantly controls critical bleeding by sealing the skin closed to create a temporary pool of blood under pressure. This forms a clot which stabilizes the wound until surgical repair. Other devices such as tourniquets and wound packs containing blood clotting agents are often limited in where they can be applied on the body, take between 5 and 15 minutes to apply, and require detailed training for correct application. The ITClamp is cost-effective, fast, intuitive, versatile, safe and efficacious.

- **How does the ITClamp compare to a tourniquet?**

The ITClamp is more versatile than a tourniquet because it can be used for multiple indications and does not stop the flow of blood to the extremity as with tourniquets. Tourniquets are useful in amputations and some extremity wounds but they cannot address junctional (groin, armpit, or neck) injuries, scalp wounds or open chest and abdominal injuries. One or more ITClamps can be applied almost anywhere on the body, depending on the size of the wound, to temporarily halt bleeding or provide wound closure.

- **What if the wound is larger than the ITClamp device?**

Multiple ITClamps can be used on one wound, depending on the size of the wound, to temporarily stop external hemorrhage.

- **How difficult is the device to use?**

The ITClamp is very easy to apply – align the device within an inch of the wound edges and squeeze the ITClamp closed to create a fluid or air tight seal.

- **How painful is the ITClamp?**

The only pain associated with the ITClamp is the insertion of the needles into the skin, which is comparable to a needle poke one might experience with getting an injection. When the ITClamp is closed to seal the wound, the patient might experience a mild sense of pressure, but the pressure is evenly distributed along the wound edge and does not crush the tissues.

- **How did ITC originate?**

After retiring from 20 years of service with the Canadian Forces, ITC's founder, Dr. Dennis Filips, taught surgical skills to medics deploying to Afghanistan. He saw a need to enable medics and soldiers to treat bleeding, the leading cause of trauma death, much earlier than what current devices allowed and with far less technical skill or knowledge. A vision emerged to create a device that was so simple and novel that anyone could learn to use it within seconds. Together with Chief Technology Officer Dr. Ian Atkinson's product development experience from California, the company was founded in 2010.

MANAGEMENT TEAM

Philip Faris Jr. EXECUTIVE CHAIRMAN OF THE BOARD

Mr. Faris has a distinguished track record of building market-leading companies in emerging medical markets and has successfully performed as CEO for over three decades in start-up, early stage, and high-growth organizations. He is currently CEO and managing partner at ProSavant International, a strategic consulting firm for the medical device and biotechnology space. He also serves as Lead Director and Senior Advisor at Advanced Circulatory System, Inc., a Minnesota based perfusion therapy medical device manufacturer; on the Executive Committee of Biomed SA, a non-profit organization promoting the bioscience industry in San Antonio, Texas; and as a Board Member and Senior Advisor for Vivo Biosciences, an Alabama-based biotechnology company. Through his career, Faris has acted as CEO and Director at Vidacare Corporation, VidiMedix Corporation, Trestle Corporation, Diatek Corporation and many other medical device, biotechnology and health care companies.

Commander (Ret'd) Dennis F. Filips, MD, FRCSC FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Dr. Filips, is the principal founder, President, and CEO of ITC, Inc. Dr. Filips, a trauma surgeon, retired from the Canadian Forces (CF) after 20 years of service, completing tours in Afghanistan, Bosnia, and the Golan Heights. He created the Tactical Combat Casualty Care training program, created and chaired the Combat Casualty Working Group for the Canadian Forces, and was a member of the Combat Casualty Care research steering committee for Canada, US, UK, Australia, and New Zealand. Dr. Filips recently carried out consulting research work for Defence Research and Development Canada (DRDC) on combat injury assessment and prevention research. Prior to this he published research findings on hypertonic fluid resuscitation and hemorrhage control with tourniquets.

Dr. Filips is currently serving as a course director for Advanced Trauma Life Support (ATLS) courses at the University of Alberta and Tactical Medicine courses for the military and tactical police. He also worked in Haiti with the Red Cross as the chief surgeon at the Notre Dame Hospital in Petit Goave post-earthquake, and is a member of the management team for the Canadian Red Cross rapid deployment field hospital. He has practiced trauma and general surgery at St. Michael's hospital in Toronto, St. Joseph's Health Centre in Toronto and at the University of Alberta in Edmonton. In addition to a trauma fellowship at Sunnybrook & Women's College Health Sciences Centre in Toronto, ON in 2002, he has completed several military trauma-training courses in Los Angeles, CA, Geneva, Switzerland, and London, UK. He completed his general surgery residency at the University of Toronto in 2001 and medical school at Queen's University (Kingston, ON) in 1991.

Ian Atkinson, PhD. FOUNDER, CHIEF TECHNOLOGY OFFICER

Dr. Atkinson brings extensive industry experience in technology development, project management, and systems optimization across a broad range of medical, drug development, genomics and biological applications. Prior to joining ITC, Dr. Atkinson was the chief scientific officer of Biobasix Solutions Inc., a management-consulting firm that developed novel therapeutics for rare disease. His experience includes roles of increasing responsibility in companies including Spiritus Diagnostics, Illumina, Molecular Dynamics/Amersham Pharmacia, and Ignition Sequence. He holds a combined PhD in Genetics and Biological Sciences from the University of Alberta, and conducted his post-doctoral research at the University of California, Berkeley.

Steve Burt, CPA CHIEF FINANCIAL OFFICER

Mr. Burt offers a unique combination of operational and financial experience in early stage and middle market technology and service companies. He served as Partner with PricewaterhouseCoopers, LLP. As the lead partner in the Bay Area New Media assurance practice, he led numerous technology IPO transactions. In addition, he led PwC's Austin, Texas based Southwest Region Technology Information Communications and Entertainment practice. Mr. Burt has served as CFO for several venture-based technology companies, a private equity backed retail franchisor, and has served as CEO for a wholesale middle market distributor.

Steve Dralle VICE PRESIDENT OF MARKETING

Mr. Dralle brings a wealth of experience in marketing, management and clinical application to ITC. Prior to joining ITC, he served as the Director of Marketing for Vidacare Corporation and as the General Manager, South Division of American Medical Response, the nation's largest private ambulance service. Additionally, with 20 years of experience as a licensed Paramedic and his service as a combat medical specialist in the U.S. Army National Guard, Mr. Dralle knows the clinical aspects of the emergency medicine market thoroughly. Mr. Dralle holds an MBA from Pennsylvania State University at University Park and received his B.A. in History from the University of Texas at San Antonio.

Gamal Soliman, MD VICE PRESIDENT OF INTERNATIONAL SALES

Dr. Soliman brings extensive international experience in the medical device and healthcare markets in Europe, Middle East, Africa and Asia. He has a successful record of establishing and managing international distribution and dealer networks, as well as successfully launching emerging medtech products through high performance sales organizations. Prior to joining Innovative Trauma Care, Dr. Soliman led international sales for Vidacare Corporation, and earlier for Trestle Corporation. Dr. Soliman directed sales and marketing functions in the Middle East and Africa for Johnson and Johnson, APTECH Corporation and US Surgical Corporation. Dr. Soliman received his Medicine and Surgery M.B.B.CH (MD) degree from Tanta University, Tanta, Egypt in 1988.

Richard T. Waite SENIOR DIRECTOR OF QUALITY ASSURANCE AND REGULATORY AFFAIRS

Mr. Waite, Sr. Director of Quality Assurance and Regulatory Affairs, is an experienced healthcare medical device professional. He has over 10 years' experience in the management of Quality Assurance and Regulatory Affairs in the medical device field. Prior to joining ITC, Waite was the Director of Quality Assurance and Regulatory Affairs of Vidacare Corporation, a global medical device company that develops and manufactures an emergency care intraosseous infusion and bone marrow aspiration and biopsy products.

BOARD OF DIRECTORS

Philip W. Faris, Jr. EXECUTIVE CHAIRMAN OF THE BOARD

Mr. Faris has a distinguished track record of building market-leading companies in emerging medical markets and has successfully performed as CEO for over three decades in start-up, early stage, and high-growth organizations. He is currently CEO and managing partner at ProSavant International, a strategic consulting firm for the medical device and biotechnology space. He also serves as Lead Director and Senior Advisor at Advanced Circulatory System, Inc., a Minnesota based perfusion therapy medical device manufacturer; on the Executive Committee of Biomed SA, a non-profit organization promoting the bioscience industry in San Antonio, Texas; and as a Board Member and Senior Advisor for Vivo Biosciences, an Alabama-based biotechnology company. Through his career, Faris has acted as CEO and Director at Vidacare Corporation, VidiMedix Corporation, Trestle Corporation, Diatek Corporation and many other medical device, biotechnology and health care companies.

John Pinsent, CA SENIOR ASSOCIATE, ST. ARNAUD PINSENT STEMAN CHARTERED ACCOUNTANTS

CHAIR OF THE AUDIT COMMITTEE

Mr. Pinsent is a founding partner of St. Arnaud Pinsent Steman Chartered Accountants, following a distinguished career with Ernst and Young LLP as an Assurance Senior Manager and as Director of Technology, Communication and Entertainment (TCE) assurance services for Northern Alberta. At St. Arnaud, Pinsent specializes in the provision of accounting, audit, tax and business advisory services for owner-managed businesses. Mr. Pinsent has a particular passion for assisting early stage technology and biotechnology companies and has been an active angel investor and mentor to organizations in this space. During his many years in public practice, he has built a strong network of contacts from various industries, and he regularly uses this support network to help his clients and investee companies build value for their enterprises.

Dr. Ruth Collins-Nakai MD, MBA, FRCPC, MACC, ICD.D BOARD MEMBER

CHAIR OF THE COMPENSATION COMMITTEE

Dr. Ruth Collins-Nakai, an internationally respected pediatric and adult congenital cardiologist, divides her time between clinical practice and health care consulting. She spent over 30 years at the University of Alberta in various roles including Full Professor and Associate Dean of the Faculty of Medicine & Dentistry and has served as Commissioner on the Premier's Commission on Future Health Care for Albertans, President of the Alberta Medical Association, Chair of the Board of Governors of the American College of Cardiology, President of the Canadian Cardiovascular Society, President of the InterAmerican Society of Cardiology, as one of the founding members of the Governing Council of the Canadian Institutes of Health Research, and in 2005-2006, as President of the Canadian Medical Association. In 2001 the International Academy of Cardiovascular Sciences awarded her its Distinguished Achievement Award for promoting cardiovascular education and research throughout the world and in 2005 was recognized as one of Alberta's 100 Physicians of the Century. She has also been honored with the YWCA's Women of Distinction Lois E. Hole's Lifetime Achievement Award and the Canadian Medical Association's Medal of Service. She has been named a "Distinguished Citizen" by Grant MacEwan College and in June 2009 was recognized and installed in the Edmonton Hall of Fame for her service to community. In the health and research sphere, she currently serves on the boards of, among others, Genome Alberta and Alberta Health Services.

Randy Thompson CEO OF VA ANGELS, BOARD MEMBER

R Stewart (Randy) Thompson has been involved with technology start-ups since 1990. As a founder of the first Internet Service Provider in Alberta, Canada, and his building of the first two angel groups in Alberta, Randy has put an active stamp on well over 100 start-ups in Western Canada, USA, and the UK. Currently, Randy is the CEO of the VA Angels Forum, which has funded \$28.5 million since its inception. With over 70 members across Western Canada, the forum has funded 61 companies since 2003. Randy also built Deal Generator, an Angel group of TEC Edmonton and Innovate Calgary, and was a Chapter President for a Keiretsu Forum chapter from 2003 to 2005. His background has led him to speak on Angel investing in China, the US, and London, UK as well as be a panelist at both the Angel Capital Association (ACA) and the National Angel Capital Organization (NACO) in Canada. Randy has been a NACO board member, an angel investor, advisor, and board member in 13 companies, all in the telco, digital media, digital content, and life sciences.

Commander (Ret'd) Dennis F. Filips, MD, FRCSC FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER,
BOARD MEMBER

Dr. Filips, is the principal founder, President, and CEO of ITC, Inc. Dr. Filips, a trauma surgeon, retired from the Canadian Forces (CF) after 20 years of service, completing tours in Afghanistan, Bosnia, and the Golan Heights. He created the Tactical Combat Casualty Care training program, created and chaired the Combat Casualty Working Group for the Canadian Forces, and was a member of the Combat Casualty Care research steering committee for Canada, US, UK, Australia, and New Zealand. Dr. Filips recently carried out consulting research work for Defence Research and Development Canada (DRDC) on combat injury assessment and prevention research. Prior to this he published research findings on hypertonic fluid resuscitation and hemorrhage control with tourniquets.

Dr. Filips is currently serving as a course director for Advanced Trauma Life Support (ATLS) courses at the University of Alberta and Tactical Medicine courses for the military and tactical police. He also worked in Haiti with the Red Cross as the chief surgeon at the Notre Dame Hospital in Petit Goave post-earthquake, and is a member of the management team for the Canadian Red Cross rapid deployment field hospital. He has practiced trauma and general surgery at St. Michael's hospital in Toronto, St. Joseph's Health Centre in Toronto and at the University of Alberta in Edmonton. In addition to a trauma fellowship at Sunnybrook & Women's College Health Sciences Centre in Toronto, ON in 2002, he has completed several military trauma-training courses in Los Angeles, CA, Geneva, Switzerland, and London, UK. He completed his general surgery residency at the University of Toronto in 2001 and medical school at Queen's University (Kingston, ON) in 1991.

Ian Atkinson, PhD. FOUNDER, CHIEF TECHNOLOGY OFFICER, BOARD MEMBER

Dr. Atkinson brings extensive industry experience in technology development, project management, and systems optimization across a broad range of medical, drug development, genomics and biological applications. Prior to joining ITC, Dr. Atkinson was the chief scientific officer of Biobasix Solutions Inc., a management-consulting firm that developed novel therapeutics for rare disease. His experience includes roles of increasing responsibility in companies including Spiritus Diagnostics, Illumina, Molecular Dynamics/Amersham Pharmacia, and Ignition Sequence. He holds a combined PhD in Genetics and Biological Sciences from the University of Alberta, and conducted his post-doctoral research at the University of California, Berkeley.